Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF | Spanish ecancer 9 526 / https://doi.org/10.3332/ecancer.2015.526

Special Issue

The role of human papillomaviruses in carcinogenesis

The human papillomavirus (HPV) family comprises more than 170 different types that preferentially infect the mucosa of the genitals, upper-respiratory tract, or the skin. The ‘high-risk HPV type’, a sub-group of mucosal HPVs, is the cause of approximately 5% of all human cancers, which corresponds to one-third of all virus-induced tumours. Within the high-risk group, HPV16 is the most oncogenic type, being responsible for approximatively 50% of all worldwide cervical cancers. Many studies suggest that, in addition to the high-risk mucosal HPV types, certain cutaneous HPVs also have a role in the development of non-melanoma skin cancer (NMSC).

Functional studies on the HPV early gene products showed that E6 and E7 play a key role in carcinogenesis. These two proteins use multiple mechanisms to evade host immune surveillance, allowing viral persistence, and to deregulate cell cycle and apoptosis control, thus facilitating the accumulation of DNA damage and ultimately cellular transformation.

The demonstration that high-risk HPV types are the etiological agents of cervical cancer allowed the implementation in the clinical routine of novel screening strategies for cervical lesions, as well as the development of a very efficient prophylactic vaccine. Because of these remarkable achievements, there is no doubt that in the coming decades we will witness a dramatic reduction of cervical cancer incidence
worldwide.

Keywords: papillomavirus, carcinogenesis, HPV vaccines

Loading Article Metrics ... Please wait

Related articles

Research: Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies

Abstract | Full Article | PDF Published: 10 Jul 2019 / https://doi.org/10.3332/ecancer.2019.937

Review: Challenges and shifting paradigms in clinical trials in oncology, the case for immunological and targeted therapies

Abstract | Full Article | PDF Published: 05 Jul 2019 / https://doi.org/10.3332/ecancer.2019.936

Research: Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

Abstract | Full Article | PDF Published: 27 Jun 2019 / https://doi.org/10.3332/ecancer.2019.935

Research: Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy

Abstract | Full Article | PDF Published: 06 Jun 2019 / https://doi.org/10.3332/ecancer.2019.934

Case Report: Two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as follicular gastritis

Abstract | Full Article | PDF Published: 03 Jun 2019 / https://doi.org/10.3332/ecancer.2019.933



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation